| Target Price | $15.81 |
| Price | $4.20 |
| Potential |
276.43%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Evolent Health Inc Class A 2026 .
The average Evolent Health Inc Class A target price is $15.81.
This is
276.43%
register free of charge
$21.00
400.00%
register free of charge
$9.09
116.43%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend Evolent Health Inc Class A to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Evolent Health Inc Class A stock has an average upside potential 2026 of
276.43%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.55 | 1.90 |
| 30.09% | 25.51% | |
| EBITDA Margin | 4.53% | 8.06% |
| 34.65% | 77.82% | |
| Net Margin | -3.66% | 1.46% |
| 49.50% | 139.91% |
15 Analysts have issued a sales forecast Evolent Health Inc Class A 2025 . The average Evolent Health Inc Class A sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Evolent Health Inc Class A EBITDA forecast 2025. The average Evolent Health Inc Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Evolent Health Inc Class A Analysts have issued a net profit forecast 2025. The average Evolent Health Inc Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.81 | 0.25 |
| 36.72% | 130.86% | |
| P/E | 16.90 | |
| EV/Sales | 0.74 |
15 Analysts have issued a Evolent Health Inc Class A forecast for earnings per share. The average Evolent Health Inc Class A EPS is
This results in the following potential growth metrics and future valuations:
Evolent Health Inc Class A...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 21 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 17 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 14 2025 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 12 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Citizens |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 21 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 17 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 14 2025 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 12 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
Citizens:
Locked
➜
Locked
|
Nov 10 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


